A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetic and efficacy of
fisogatinib (formerly known as BLU-554) in combination with CS1001 in patients with locally
advanced or metastatic hepatocellular carcinoma (HCC)